(19)
(11) EP 3 395 339 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.12.2019 Bulletin 2019/50

(45) Mention of the grant of the patent:
17.04.2019 Bulletin 2019/16

(21) Application number: 18175497.9

(22) Date of filing: 10.09.2004
(51) International Patent Classification (IPC): 
A61K 31/135(2006.01)
A61K 9/20(2006.01)
 A61K 9/28(2006.01)
A61P 5/18(2006.01)

(54)

RAPID DISSOLUTION FORMULATION OF A CINACALCET HCL

SCHNELLAUFLÖSUNGSFORMULIERUNG ENTHALTEND CINACALCET HCL

FORMULATION À DISSOLUTION RAPIDE DE CINACALCET HCL

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 12.09.2003 US 502219 P

(43) Date of publication of application:
31.10.2018 Bulletin 2018/44

(62) Application number of the earlier application in accordance with Art. 76 EPC:
17185704.8 / 3260117
14163366.9 / 2821067
10014567.1 / 2316442
04781429.8 / 1663182

(73) Proprietor: Amgen Inc.
Thousand Oaks, CA 91320-1799 (US)

(72) Inventors:
  • ÁLVAREZ, Francisco J.
    Newbury Park, CA California 91320 (US)
  • JU, Tzuchi R.
    Vernon Hills, IL Illinois 60061 (US)
  • LIN, Hung-Ren H.
    Oak Park, CA California 91377 (US)
  • LAWRENCE, Glen Cary
    Thousand Oaks, CA California 91320-1799 (US)

(74) Representative: EIP 
EIP Europe LLP Fairfax House 15 Fulwood Place
London WC1V 6HU
London WC1V 6HU (GB)


(56) References cited: : 
US-B1- 6 211 244
 US-B1- 6 313 146
   
  • ANONYMOUS: "Amgen submitted new drug application for Cinacalcet HCI", AMGEN NEWS RELEASE , 8 September 2003 (2003-09-08), XP002313388, Retrieved from the Internet: URL:http://www.amgen.com/news/news03/press Release030908a.pdf [retrieved on 2005-01-12]
  • GOODMAN WILLIAM G ET AL: "The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN. APR 2002, vol. 13, no. 4, April 2002 (2002-04), pages 1017-1024, XP002313387, ISSN: 1046-6673
  • ANONYMOUS: "NPS-Drug Development: Product Develpment Pipeline", INTERNET ARTICLE , 8 September 2003 (2003-09-08), XP002313391, Retrieved from the Internet: URL:www.npsp.com/drug_development/pipeline .php [retrieved on 2005-01-12]
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).